Infection with Burkholderia cepacia in cystic fibrosis -: Outcome following lung transplantation

被引:172
作者
Chaparro, C
Maurer, J
Gutierrez, C
Krajden, M
Chan, C
Winton, T
Keshavjee, S
Scavuzzo, M
Tullis, E
Hutcheon, M
Kesten, S
机构
[1] Univ Toronto, Toronto Hosp, Toronto Lung Transplant Program, Toronto, ON, Canada
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[4] Univ Toronto, Wellesley Hosp, Adult Cyst Fibrosis Clin, Toronto, ON M4Y 1J3, Canada
关键词
D O I
10.1164/ajrccm.163.1.9811076
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
As a result of concern over excessive mortality after lung transplantation, many transplant programs refuse to accept cystic fibrosis (CF) patients infected with Burkholderia cepacia. As a significant proportion of patients with CF in our community are infected with this organism, we have continued to provide lung transplantation as an option. A retrospective review was conducted of medical records of all patients with CF transplanted between March 1988 and September 1996. Fifty-six transplant procedures were performed in 53 recipients with CF between March 1988 and September 1996. Twenty-eight had B, cepacla isolated pretransplant and 25 remaining positive post-transplant. Of the 53 recipients, 79 have died (15 of 28 [54%] B. cepacia positive and 4 of 25 [16%] B. cepacia negative). B. cepacia was responsible for or involved in 14 deaths. Nine of the deaths occurred in the first 3 mo posttransplantation. One-year survival was 67% for B. cepacia positive patients and 92% for B. cepacia negative patients. Recent modifications in antimicrobial and immunosuppressive therapy since 1995 have resulted in no deaths early post-transplant in the last five patients transplanted. We conclude that early mortality in patients with CF infected with B, cepacia is significantly higher than in those not infected with B, cepacia. Modifications in post-transplant medical therapy may improve outcome.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 42 条
  • [1] The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome
    Aris, RM
    Gilligan, PH
    Neuringer, IP
    Gott, KK
    Rea, J
    Yankaskas, JR
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (05) : 1699 - 1704
  • [2] INVITRO ACTIVITIES OF COMBINATIONS OF AZTREONAM, CIPROFLOXACIN, AND CEFTAZIDIME AGAINST CLINICAL ISOLATES OF PSEUDOMONAS-AERUGINOSA AND PSEUDOMONAS-CEPACIA FROM PATIENTS WITH CYSTIC-FIBROSIS
    BOSSO, JA
    SAXON, BA
    MATSEN, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) : 487 - 488
  • [3] COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713
  • [4] Dawson KG, 1999, PEDIATR INFECT DIS J, V18, P816, DOI [10.1097/00006454-199909000-00014, 10.1097/00006454-199902000-00015]
  • [5] DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633
  • [6] DENNIS C, 1993, J HEART LUNG TRANSPL, V12, P893
  • [7] DINWIDDIE R, 1993, J ROY SOC MED, V86, P7
  • [8] IMPROVED RESULTS OF LUNG TRANSPLANTATION FOR PATIENTS WITH CYSTIC-FIBROSIS
    EGAN, TM
    DETTERBECK, FC
    MILL, MR
    PARADOWSKI, LJ
    LACKNER, RP
    OGDEN, WD
    YANKASKAS, JR
    WESTERMAN, JH
    THOMPSON, JT
    WEINER, MA
    CAIRNS, EL
    WILCOX, BR
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (02) : 224 - 235
  • [9] INFECTIOUS COMPLICATIONS OF LUNG TRANSPLANTATION - IMPACT OF CYSTIC-FIBROSIS
    FLUME, PA
    EGAN, TM
    PARADOWSKI, LJ
    DETTERBECK, FC
    THOMPSON, JT
    YANKASKAS, JR
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (06) : 1601 - 1607
  • [10] GEDDES DM, 1988, CHEST, V94, pS140